Lilly to Acquire SiteOne Therapeutics to Advance Non-Opioid Pain Treatments | The Healthcare Technology Report.

▤ Summary

Eli Lilly agreed to acquire SiteOne Therapeutics in a deal worth up to $1 billion. SiteOne develops small-molecule sodium channel inhibitors for pain and related disorders, including its lead candidate STC-004. Lilly plans to advance the asset toward Phase 2 as part of its push into non-opioid pain therapies. The transaction is still subject to customary closing conditions. The deal strengthens Lilly’s neuroscience and chronic pain pipeline.

▦ Linked Companies